What is Casma Therapeutics?
Founded in 2018 and headquartered in Cambridge, Massachusetts, Casma Therapeutics is a biotechnology company dedicated to harnessing the body's natural cellular recycling process, known as autophagy. By modulating this fundamental biological mechanism, the company aims to address a wide array of diseases that have historically been considered undruggable. Casma's platform technology is designed to identify and validate novel targets, offering a transformative approach to drug discovery that could redefine treatment paradigms for neurodegenerative, inflammatory, and metabolic conditions. The company's market position is defined by its scientific rigor and its ability to bridge the gap between basic cellular biology and scalable pharmaceutical development.
How much funding has Casma Therapeutics raised?
Casma Therapeutics has raised a total of $46M across 1 funding round:
Series C
$46M
Series C (2022): $46M with participation from Eisai Global, Euclidean Capital, Astellas Venture Management, and Mirae Asset Financial Group
Key Investors in Casma Therapeutics
Eisai Global
Eisai is a global pharmaceutical manufacturing company founded in 1941 that focuses on a human health care approach, maintaining a significant emphasis on research and development in the pharmaceutical sector.
Astellas Venture Management
Founded in 2005 and headquartered in Brisbane, California, Astellas Venture Management is the corporate venture capital organization dedicated to reinforcing Astellas Pharma Inc.
Mirae Asset Financial Group
Mirae Asset Securities & Investments (USA) is a subsidiary of a global financial group providing comprehensive services including asset management, wealth management, and investment banking.
What's next for Casma Therapeutics?
With the successful closure of this latest financing, Casma Therapeutics is well-positioned to scale its research and development efforts. The strategic focus will likely shift toward advancing its lead candidates through preclinical milestones and into human clinical trials. As the company continues to refine its autophagy-based platform, it will likely seek to deepen its collaborative efforts with global pharmaceutical partners to validate its therapeutic assets. The infusion of capital serves as a critical catalyst for the firm's long-term growth strategy, enabling the expansion of its internal team and the acquisition of advanced laboratory infrastructure necessary to maintain its competitive edge in the biotech sector.
See full Casma Therapeutics company page
